Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de nipocalimabe em adultos com síndrome de Sjogren primária (pSS)

15 de outubro de 2026 atualizado por: Janssen Research & Development, LLC

Um estudo randomizado, controlado por placebo, duplo-cego, multicêntrico para avaliar a eficácia e a segurança do nipocalimabe em adultos com síndrome de Sjögren primária (pSS)

The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

163

Estágio

  • Fase 2

Acesso expandido

Temporariamente indisponível fora do ensaio clínico. Consulte registro de acesso expandido.

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Berlin, Alemanha, 10117
        • Charite Universitaetsmedizin Berlin
      • Cologne, Alemanha, 50923
        • Uniklinik Köln
      • Dresden, Alemanha, 01307
        • Universitatsklinikum Carl Gustav Carus Dresden
      • Hamburg, Alemanha, 20095
        • Hamburger Rheuma Forschungszentrum II
      • Kirchheim unter Teck, Alemanha, 73230
        • medius KLINIK KIRCHHEIM
      • Tübingen, Alemanha, 72076
        • Universitatsklinikum Tubingen
      • A Coruña, Espanha, 15006
        • Hosp Univ A Coruna
      • Córdoba, Espanha, 14004
        • Hosp Reina Sofia
      • Mérida, Espanha, 6800
        • Hosp. de Merida
      • Sabadell, Espanha, 08208
        • Corporacio Sanitari Parc Tauli
      • Salamanca, Espanha, 37007
        • Hosp Clinico Univ de Salamanca
      • Seville, Espanha, 41010
        • Hosp. Infanta Luisa
    • Alabama
      • Anniston, Alabama, Estados Unidos, 36207
        • Anniston Medical Clinic
    • Arizona
      • Glendale, Arizona, Estados Unidos, 85306
        • Arizona Arthritis and Rheumatology Research PLLC
      • Mesa, Arizona, Estados Unidos, 85210
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Fullerton, California, Estados Unidos, 92835
        • St. Jude Heritage Medical Group
      • Upland, California, Estados Unidos, 91786
        • Inland Rheumatology Clinical Trials, Inc.
    • Colorado
      • Denver, Colorado, Estados Unidos, 80230
        • Denver Arthritis Clinic
      • Denver, Colorado, Estados Unidos, 80228
        • Colorado Arthritis Associates
    • Florida
      • Boca Raton, Florida, Estados Unidos, 33486
        • Rheumatology Associates Of South Florida
      • Brandon, Florida, Estados Unidos, 33511
        • Bay Area Arthritis and Osteoporosis
      • Fort Lauderdale, Florida, Estados Unidos, 33309
        • Centre for Rheumatology, Immunology and Arthritis
      • Jacksonville, Florida, Estados Unidos, 32209
        • University of Florida Health Jacksonville
      • Orlando, Florida, Estados Unidos, 32835
        • Omega Research Consultants
    • Illinois
      • Gurnee, Illinois, Estados Unidos, 60031
        • Clinical Investigation Specialists
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
        • University of Iowa Hospitals and Clinics
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • University of Kansas Medical Center
    • Minnesota
      • Eagan, Minnesota, Estados Unidos, 55121
        • St. Paul Rheumatology P A
    • Mississippi
      • Tupelo, Mississippi, Estados Unidos, 38801
        • North Mississippi Medical Clinics
    • North Carolina
      • Salisbury, North Carolina, Estados Unidos, 28144
        • PMG Research of Salisbury
    • Pennsylvania
      • Duncansville, Pennsylvania, Estados Unidos, 16635
        • Altoona Center For Clinical Research
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • University of Pennsylvania
    • South Carolina
      • Columbia, South Carolina, Estados Unidos, 29204
        • Columbia Arthritis Center
    • Tennessee
      • Jackson, Tennessee, Estados Unidos, 38305
        • West Tennessee Research Institute
      • Memphis, Tennessee, Estados Unidos, 38119
        • Dr. Ramesh Gupta
    • Texas
      • Austin, Texas, Estados Unidos, 78731-3146
        • Austin Regional Clinic
      • Carrollton, Texas, Estados Unidos, 75007
        • Trinity Clinical Research, LLC
      • La Tronche, França, 38700
        • CHU de Grenoble Hopital Albert Michallon
      • Le Mans, França, 72037
        • Centre Hospitalier Le Mans
      • Marseille, França, 13285
        • Hopital Saint Joseph
      • Paris, França, 75013
        • Hopital Pitie Salpetriere
      • Strasbourg, França, 67098
        • CHRU Hôpital de Hautepierre
      • Leeuwarden, Holanda, 8934 AD
        • Medisch Centrum Leeuwarden
      • Rotterdam, Holanda, 3015 GD
        • Erasmus Medisch Centrum
      • Brescia, Itália, 25123
        • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
      • Catania, Itália, 95100
        • P.O. Vittorio Emanuele Azienda Ospedaliero Universitaria 'Policlinico Vittorio Emanuele'
      • Milan, Itália, 20132
        • IRCCS Ospedale San Raffaele
      • Palermo, Itália, 90129
        • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
      • Verona, Itália, 37126
        • Azienda Ospedaliera Universitaria Integrata Verona
      • Fuchū, Japão, 183 8524
        • Tokyo Metropolitan Tama Medical Center
      • Nagasaki, Japão, 852-8501
        • Nagasaki University Hospital
      • Sapporo, Japão, 060-8648
        • Hokkaido University Hospital
      • Tokyo, Japão, 104 8560
        • St. Luke's International Hospital
      • Tokyo, Japão, 173 8610
        • Nihon University Itabashi Hospital
      • Tsukuba, Japão, 305-8520
        • University of Tsukuba Hospital
      • Bydgoszcz, Polônia, 85-065
        • Nasz Lekarz Przychodnie Medyczne
      • Bydgoszcz, Polônia, 85-168
        • Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy
      • Gmina Końskie, Polônia, 26 200
        • Zespolu Opieki Zdrowotnej w Konskich
      • Krakow, Polônia, 30-002
        • Malopolskie Badania Kliniczne Sp z o o
      • Lublin, Polônia, 20-607
        • REUMED Zespol Poradni Specjalistycznych Filia nr 2
      • Poznan, Polônia, 61 113
        • Centrum Medyczne
      • Warsaw, Polônia, 00-874
        • Medycyna Kliniczna
      • Warsaw, Polônia, 02 637
        • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
      • Warsaw, Polônia, 03 291
        • Centrum Medyczne AMED Targowek
      • Wroclaw, Polônia, 52 415
        • Centrum Medyczne Oporow
      • Lisbon, Portugal, 1050-034
        • Instituto Portugues de Reumatologia
      • Ponte de Lima, Portugal, 4990-078
        • ULSAM, EPE - Hospital Conde de Bertiandos
      • Taipei, Taiwan, 11490
        • Tri-Service General Hospital
      • Taoyuan, Taiwan, 333
        • Chang Gung Memorial Hospital Linkou Branch

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Meets classification criteria for primary Sjogren's syndrome (pSS) by the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) at the time of screening (results either obtained during screening or documented in the participant's medical history are acceptable to fulfill these criteria for Schirmer's test, unstimulated salivary flow test, ocular staining score, or labial salivary gland biopsy), and was diagnosed with pSS no less than 26 weeks prior to screening
  • At screening is seropositive for antibodies to pSS-associated antigen A (Ro/Sjogren's syndrome-related antigen A [SSA])
  • Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) score greater than or equal to (>=) 6
  • At least one abnormal laboratory marker of pSS-related inflammatory disease activity, and at least low activity in one or more specified European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) domains
  • It is recommended to be up to date on all age-appropriate vaccinations prior to screening per routine local medical guidelines. It is strongly recommended that participants will have completed a locally-approved (or emergency use-authorized) coronavirus disease 2019 (COVID-19) vaccination regimen at least 2 weeks prior to study related visits or procedures. Study participants should, follow applicable local vaccine labelling, guidelines, and standards-of-care for participants receiving immune-targeted therapy will be followed when determining an appropriate interval between vaccination and study enrollment

Exclusion Criteria:

  • Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her pSS or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
  • Comorbidities (for example, asthma, chronic obstructive pulmonary disease) which have required 3 or more courses of systemic glucocorticoids within the previous 12 months
  • Has any unstable or progressive manifestation of pSS that is likely to warrant escalation in therapy beyond permitted background medications and/or has severely active pSS
  • Has received oral cyclophosphamide within 3 months or intravenous (IV) cyclophosphamide within 6 months prior to first administration of study intervention
  • Has Sjogren's syndrome overlap syndromes where another confirmed autoimmune rheumatic or systemic inflammatory condition (for example, rheumatoid arthritis [RA], systemic lupus erythematosus [SLE], scleroderma, inflammatory bowel disease [IBD]) is the primary diagnosis or has clinical manifestations that, in the opinion of the investigator, or the sponsor or sponsor's representative, are likely to interfere with the investigator's ability to assess pSS manifestations

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Group 1: Placebo

Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Placebo infusion will be administered intravenously.

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Experimental: Group 2: Nipocalimab Dose 1

Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.

Outros nomes:
  • JNJ-80202135
  • M281
Experimental: Group 3: Nipocalimab Dose 2

Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.

Outros nomes:
  • JNJ-80202135
  • M281

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24
Prazo: Baseline (Week 0), Week 24

In clinESSDAI, physician scores systemic disease activity level on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 levels (no, low, moderate, high) according to their severity as assessed by investigator based on pre-defined criteria. The activity-level score ranges from 0 to 3, where 0=no disease activity and 3=high disease activity. Not all domain include all 4 activity level. Each domain was assigned weight between 1 and 7; activity-level score is multiplied by corresponding domain weight to obtain weighted domain score. Each domain has specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score is overall score, which range from 0 to 135, where lower score=no symptom and higher score=severe symptom. A decrease from baseline indicated improvement.

Baseline (Week 0), Week 24

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24
Prazo: Baseline (Week 0), Week 24

Change from baseline in ESSPRI score at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjögren's Syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

Baseline (Week 0), Week 24
Percentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
Prazo: Baseline (Week 0), Week 24

ESSDAI covers 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological) and 1 biological domain. Activity in each domain was scored at 3 to 4 level (no/low/moderate/high) according to severity as assessed by investigator based on criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain have 4 activity level). Each domain was assigned weight range from 1 to 6. Activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall ESSDAI score, ranging from 0 to 123 (0=no systemic disease activity, higher score indicated greater systemic disease activity). Decrease from baseline meant improvement.

Baseline (Week 0), Week 24
Percentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 24
Prazo: Baseline (Week 0), Week 24

In clinESSDAI, physician score systemic disease activity level on 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 level (no/low/moderate/high) according to their severity assessed by investigator based on predefined criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain include 4 activity level). Each domain was assigned weight from 1 to 7; activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall score ranging from 0 to 135 (lower score=no symptom, higher score=severe symptom). Decrease from baseline indicated improvement.

Baseline (Week 0), Week 24
Percentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24
Prazo: Baseline (Week 0), Week 24

Percentage of participants with ESSPRI response defined as a decrease of one point or a decrease of >= 15% from baseline at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjogren's syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

Baseline (Week 0), Week 24
Percentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24
Prazo: At Week 24

Percentage of participants with disease response according to STAR composite score at Week 24 was reported. STAR was a composite endpoint assessing multiple clinically relevant disease features. A STAR response was defined as a composite score of >=5 points in the 5 STAR domains, with weighting in parentheses: (i) decrease of >=3 in clinESSDAI score (3), (ii) decrease of >=1 point or >=15% from baseline in ESSPRI score (3), (iii) abnormal Schirmer's test at baseline and increase of >=5 millimeter (mm)/normal Schirmer's test at baseline and no change to abnormal/abnormal ocular staining score at baseline and a decrease of >=2 points/normal ocular staining score at baseline and no change to abnormal (1), (iv) increase of >=25% in unstimulated whole saliva/any increase if score is 0 at baseline (1), (v) decrease of >=25% in rheumatoid factor/decrease of >=10% in immunoglobulin G (IgG) (1). Overall score was sum of all domain weight, which range from 0 to 9 (higher score = worse outcome).

At Week 24
Percentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24
Prazo: At Week 24

DAL=level of disease activity severity (no/low/moderate/severe) in each clinESSDAI/ESSDAI domain. In clinESSDAI, physician score DAL on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral and central nervous system, hematological) with each domain activity in 3-4 level according to severity (0=no activity, 3=high activity; not all domains have 4 activity level). Each domain given weight: 1-7, activity level score * domain weight. Sum of weighted domain score was overall score (0-135: higher score=severe symptom). A decrease from baseline indicated improvement. Participants with improvement of >= 4 points (minimal clinically important improvement) were reported in this outcome measure. ESSDAI differs from clinESSDAI by adding biological domain that cover B-cell biomarker (elevated gamma-globulin/IgG level, low complement level, cryoglobulinemia, monoclonal gammopathy).

At Week 24
Percentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 24
Prazo: At Week 24

Percentage of participants with improvement from baseline in >= 3 of 5 CRESS categories at Week 24 was reported. CRESS was a composite tool that incorporates measures of disease activity (clinESSDAI), symptoms (ESSPRI), glandular function and systemic inflammation to assess disease activity. A CRESS response was defined as a response in >= 3 of the following 5 categories: (i) clinESSDAI score less than (<) 5 (low disease activity), (ii) decrease of >= 1 point or >= 15% from baseline in ESSPRI score, (iii) abnormal Schirmer's test at baseline (<= 5 mm) and an increase of >= 5 mm, or normal Schirmer's test at baseline and no change to abnormal, (iv) increase of >= 25% in unstimulated whole saliva or any increase if score is 0 at baseline, (v) decrease of >= 25% in rheumatoid factor or decrease of >= 10% in IgG.

At Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit
Prazo: Post first administration of study intervention (Week 0) up to Week 30

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit
Prazo: Post first administration of study intervention (Week 0) up to Week 30

Number of participants with AESIs were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Treatment-emergent adverse events associated with the following situations were considered AESIs. (i) Infections that were severe or require IV anti-infective or operative/invasive intervention; (ii) Hypoalbuminemia with albumin < 20 grams per liter (g/L) (< 2.0 grams per deciliter [g/dL]); applicable to participants who had albumin greater than (>) 20 g/L at previous assessments. Those who entered with < 20 g/L and stayed below this level were not reported as an AESI. Those who entered with an albumin > 20 g/L or those who entered with albumin < 20g/L and then had an increase in albumin > 20 g/L which subsequently decreased to < 20 g/L were reported as an AESI.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Through End of Study Visit
Prazo: Post first administration of study intervention (Week 0) up to Week 30

A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly or any situation deemed medically important by the investigator. Treatment-emergent SAEs were defined as SAEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With TEAEs Leading to Treatment Discontinuation Through End of Study Visit
Prazo: Post first administration of study intervention (Week 0) up to Week 30

Number of participants with TEAEs leading to treatment discontinuation were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Prazo: Post first administration of study intervention (Week 0) up to Week 30

Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs parameters including temperature (< 36 degree Celsius and > 38 degree Celsius), pulse rate (<= 50 beats per minute [bpm] and with >= 15 bpm decrease from baseline and >= 120 bpm and with >= 15 bpm increase from baseline), and blood pressure (systolic blood pressure [SBP]: <= 90 millimeters of mercury [mmHg] and with >= 20 mmHg decrease from baseline and >= 160 mmHg and with >= 20 mmHg increase from baseline; diastolic blood pressure [DBP]: <= 50 mmHg and with >= 15 mmHg decrease from baseline and >= 100 mmHg and with >= 15 mmHg increase from baseline). Only those categories in which at least 1 participant had data were reported.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Prazo: Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Laboratory parameters included hematology (platelet count [platelets: decrease > 20% and value < 100)], red blood cell count, hemoglobin, hematocrit, white blood cell count with differential [lymphocytes: decrease > 20% and value < 0.08], [leukocytes: decrease > 10% and value < 2.5], [neutrophils: increase > 30% and value > 0.90], [eosinophils: increase > 20% and value > 0.10]), serum chemistry (phosphate [decrease > 10% and value < 0.6), lipid panel (high-density lipoprotein [HDL] and low-density lipoprotein [LDL], creatine kinase: increase > 20% and value > 960, cholesterol: value >= 6.2), urinalysis, and blood coagulation. Participants were assessed at Weeks 2, 4, 8, 12, 16, 20, 24, 30 but only those categories and timepoints (Weeks 2, 4, 8, 12, 16, 24, 30) in which at least 1 participant had data were reported.

Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Serum Nipocalimab Concentration Over Time
Prazo: Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30

Serum concentrations of nipocalimab over time was reported. This outcome measure was planned to be analyzed for specified arms only.

Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30
Change From Baseline in C-reactive Protein (CRP)
Prazo: Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30

Change from baseline in CRP were reported.

Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
Prazo: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in ESR were reported. ESR was a composite outcome assessment that measures the degree of inflammation.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Change From Baseline in Total Immunoglobulin (Ig)G, IgG1, IgG2, IgG3, IgG4
Prazo: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in total IgG, IgG1, IgG2, IgG3, IgG4 were reported.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Change From Baseline in Autoantibodies : Anti-Sjogren's Syndrome Related Antigen A (Anti-Ro/SSA), Anti-Sjogren's Syndrome Related Antigen B (Anti-La/SSB), and Anti-Ro52/TRIM21
Prazo: Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30

Change from baseline in autoantibodies included anti-Ro60/SSA, anti-La/SSB, and anti-Ro52/tripartite motif-containing protein 21 (Anti-Ro52/TRIM21) were reported.

Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30
Change From Baseline in Autoantibodies: Rheumatoid Factor (RF)
Prazo: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in autoantibodies included RF were reported.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Number of Participants With Anti-drug Antibodies (ADAs) to Nipocalimab
Prazo: Baseline (Week 0) up to Week 30

Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method. This outcome measure was planned to be analyzed for specified arms only.

Baseline (Week 0) up to Week 30
Number of Participants With Neutralising Antibodies (NAbs) to Nipocalimab
Prazo: Baseline (Week 0) up to Week 30

Number of participants with NAbs were reported. Neutralising antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay. This outcome measure was planned to be analyzed for specified arms only.

Baseline (Week 0) up to Week 30

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

21 de setembro de 2021

Conclusão Primária (Real)

23 de outubro de 2023

Conclusão do estudo (Real)

30 de novembro de 2023

Datas de inscrição no estudo

Enviado pela primeira vez

9 de julho de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de julho de 2021

Primeira postagem (Real)

20 de julho de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever